This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
by Mark Vickery
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.
QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash
by Zacks Equity Research
QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.
Boston Scientific (BSX) Rides on Global Growth, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.
Top Research Reports for Microsoft, Meta & JPMorgan Chase
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Meta Platforms, Inc. (META) and JPMorgan Chase & Co. (JPM), as well a micro-cap stock Applied Energetics, Inc. (AERG).
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down
by Zacks Equity Research
Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.
3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Brokers Suggest Investing in Intuitive Surgical (ISRG): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
Intuitive Surgical and Hooker Furnishings have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intuitive Surgical and Hooker Furnishings are part of the Zacks Bull and Bear of the Day article.
Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand
by Zacks Equity Research
Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.
Bull of the Day: Intuitive Surgical (ISRG)
by Tracey Ryniec
Double digit growth is back for the maker of da Vinci.
Intuitive Surgical, Inc. (ISRG) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Intuitive Surgical, Inc. (ISRG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
by Zacks Equity Research
Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
Are Medical Stocks Lagging Intuitive Surgical (ISRG) This Year?
by Zacks Equity Research
Here is how Intuitive Surgical, Inc. (ISRG) and biote Corp. (BTMD) have performed compared to their sector so far this year.
Intuitive Surgical (ISRG) Hits All-Time High: Will It Go Higher?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported robust quarterly performance last week, and its shares touched an all-time high. Will the company's fundamentals support further upside?
Intuitive Surgical, Inc. (ISRG) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Intuitive Surgical, Inc. (ISRG) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?